Internal Medicine, Endocrinology, Diabetes, & Metabolism · Mooresville, NC
NPI
1780844621
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
170 Medical Park Rd
Mooresville, NC, 28117
Phone (704) 664-9506
Groups this clinician bills Medicare through
Medicare paid, 2024
$81K
2,654 services
Medicare patients, 2024
431
Average age 73
Drug cost, 2024
$2.7M
3,718 prescriptions
Company payments, 2025
$80K
From 32 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elaine M Sunderlin was code 99214 (office e&m - established), 358 times for 246 patients. In total Elaine M Sunderlin billed 2,654 services in 68 codes, and Medicare paid $81K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-09-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 358 | 246 | $85.66 | $31K |
| 36415 Venipuncture Blood Collection | Office | 255 | 184 | $8.65 | $2,206 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 216 | 153 | $11.57 | $2,500 |
| 84443 Clinical Chemistry | Office | 174 | 118 | $16.46 | $2,864 |
| 84439 Clinical Chemistry | Office | 161 | 105 | $8.79 | $1,414 |
| 99204 Office E&M - New | Office | 147 | 147 | $115.87 | $17K |
| 84481 Clinical Chemistry | Office | 128 | 80 | $16.60 | $2,125 |
| 83036 Blood Count | Office | 120 | 97 | $9.44 | $1,133 |
| 80053 Clinical Chemistry | Office | 96 | 86 | $10.24 | $983 |
| 95251 Test - Miscellaneous | Office | 96 | 69 | $24.08 | $2,312 |
| 76536 Ultrasound - Nonspecific | Office | 65 | 64 | $73.12 | $4,752 |
| 82306 Clinical Chemistry | Office | 54 | 52 | $28.47 | $1,538 |
| 99213 Office E&M - Established | Office | 39 | 38 | $64.25 | $2,506 |
| 84100 Clinical Chemistry | Office | 30 | 29 | $4.65 | $140 |
| 85025 Blood Count | Office | 27 | 25 | $7.61 | $205 |
By year: 2022 $112K for 4,276 services; 2023 $193K for 11,589 services; 2024 $81K for 2,654 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 255 | 184 | $8.65 | $2,206 |
| 84443 Clinical Chemistry | 174 | 118 | $16.46 | $2,864 |
| 84439 Clinical Chemistry | 161 | 105 | $8.79 | $1,414 |
| 84481 Clinical Chemistry | 128 | 80 | $16.60 | $2,125 |
| 83036 Blood Count | 120 | 97 | $9.44 | $1,133 |
| 80053 Clinical Chemistry | 96 | 86 | $10.24 | $983 |
| 82306 Clinical Chemistry | 54 | 52 | $28.47 | $1,538 |
| 84100 Clinical Chemistry | 30 | 29 | $4.65 | $140 |
| 85025 Blood Count | 27 | 25 | $7.61 | $205 |
| 82533 Clinical Chemistry | 22 | 17 | $15.97 | $351 |
Medicare prescription drug claims, 2024
In 2024, the drug Elaine M Sunderlin prescribed most often to Medicare patients was Ozempic (Semaglutide), with 398 prescriptions and refills. In total Elaine M Sunderlin wrote 3,718 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 398 | 590 | 92 | $559K |
| Levothyroxine Sodium Generic | 279 | 724 | 85 | $2,231 |
| Jardiance Empagliflozin | 211 | 430 | 62 | $250K |
| Methimazole Generic | 194 | 385 | 48 | $1,981 |
| Alendronate Sodium Generic | 133 | 338 | 44 | $961 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 130 | 295 | 50 | $14K |
| Metformin Hcl Generic | 130 | 320 | 46 | $1,080 |
| Mounjaro Tirzepatide | 125 | 166 | 33 | $173K |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 116 | 244 | 24 | $156K |
| Rosuvastatin Calcium Generic | 101 | 267 | 35 | $751 |
| Metformin Hcl Er Metformin Hcl | 94 | 251 | 30 | $919 |
| Tresiba Flextouch U-100 Insulin Degludec | 91 | 207 | 31 | $59K |
| Tresiba Flextouch U-200 Insulin Degludec | 82 | 180 | 28 | $105K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 75 | 157 | 35 | $8,630 |
| Novolog Flexpen Insulin Aspart | 75 | 151 | 30 | $23K |
Brand drugs: 2,081 claims; generic drugs: 1,210 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elaine M Sunderlin $80K ($80K in general payments such as food, travel and fees) from 32 companies. The largest payer was Novo Nordisk Inc with $74K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 70 | $74K |
| CeQur Corporation | 3 | $4,210 |
| Janssen Biotech, Inc. JNJ | 10 | $283 |
| Amgen Inc. AMGN | 17 | $266 |
| Sanofi-Aventis U.S. LLC SNY | 6 | $152 |
| Amneal Pharmaceuticals LLC AMRX | 10 | $152 |
| IBSA Pharma Inc. | 7 | $140 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 8 | $137 |
| Sequel Med Tech, LLC | 2 | $130 |
| Abbvie Inc. ABBV | 6 | $108 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.